NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Active Not RecruitingN/A

Sponsor: Hoffmann-La Roche

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion

Interventions: Faricimab, Port Delivery System with Ranibizumab

Countries: United States, Argentina, Australia, Bulgaria, Canada, Chile, Croatia, Czechia

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1\. Have provided informed consent, as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.

Exclusion Criteria:

1\. Concomitant participation of the patient in an investigational ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)

Locations (299)

Phoenix, Arizona, United States
Pasadena, California, United States
Sacramento, California, United States
Coral Springs, Florida, United States
Pensacola, Florida, United States
Lemont, Illinois, United States
Springfield, Illinois, United States
Lexington, Kentucky, United States
Hagerstown, Maryland, United States
Royal Oak, Michigan, United States
Erie, Pennsylvania, United States
Nashville, Tennessee, United States
San Antonio, Texas, United States
Southlake, Texas, United States
Salt Lake City, Utah, United States
Lynchburg, Virginia, United States
Norfolk, Virginia, United States
Spokane, Washington, United States
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Córdoba, Argentina
San Miguel de Tucumán, Argentina
Hurstville, New South Wales, Australia
Westmead, New South Wales, Australia
Geebung, Queensland, Australia
East Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Rowville, Victoria, Australia
Broome, Western Australia, Australia
+ 269 more on CT.gov